Results 11 to 20 of about 1,828,522 (388)

Pharmacokinetics of Monoclonal Antibodies

CPT: Pharmacometrics & Systems Pharmacology, 2017
Monoclonal antibodies (mAbs) have developed in the last two decades into the backbone of pharmacotherapeutic interventions in a variety of indications, with currently more than 40 mAbs approved by the US Food and Drug Administration, and several dozens more in clinical development. This tutorial will review major drug disposition processes relevant for
Bernd Meibohm, Josiah T. Ryman
openaire   +4 more sources

Neutralizing monoclonal antibodies for treatment of COVID-19

Nature reviews. Immunology, 2021
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical trials.
P. Taylor, A. Adams, M. Hufford, I. de la Torre, K. Winthrop, R. Gottlieb   +5 more
semanticscholar   +1 more source

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

bioRxiv, 2021
Monoclonal antibodies and antibody cocktails are a promising therapeutic and prophylaxis for COVID-19. However, ongoing evolution of SARS-CoV-2 can render monoclonal antibodies ineffective.
Tyler N. Starr, Allison J. Greaney, A. Dingens, J. Bloom   +3 more
semanticscholar   +1 more source

SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies

Nature, 2021
Transmission of SARS-CoV-2 is uncontrolled in many parts of the world; control is compounded in some areas by the higher transmission potential of the B.1.1.7 variant1, which has now been reported in 94 countries.
D. Collier, A. De Marco, I. Ferreira, B. Meng, R. Datir, A. Walls, Steven A Kemp S, J. Bassi, D. Pinto, C. Fregni, S. Bianchi, M. A. Tortorici, John E. Bowen, K. Culap, S. Jaconi, E. Cameroni, G. Snell, M. Pizzuto, A. F. Pellanda, C. Garzoni, A. Riva, A. Elmer, N. Kingston, B. Graves, Laura E. McCoy, Kenneth G. C. Smith, J. Bradley, Nigel James Temperton, L. Lourdes Ceron-Gutierrez, G. Barcenas-Morales, William T. Harvey, H. Virgin, A. Lanzavecchia, L. Piccoli, R. Doffinger, M. Wills, D. Veesler, D. Corti, Ravindra K. Gupta   +38 more
semanticscholar   +1 more source

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

bioRxiv, 2020
The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 800 laboratory-confirmed human infections, including 25 deaths, posing a serious threat to human health. Currently, however, there is no specific antiviral treatment or vaccine.
Xiao-long Tian, Cheng Li, Ailing Huang, Shuai Xia, Sicong Lu, Zhènglì Shí, Lu Lu, Shibo Jiang, Zhenlin Yang, Yanling Wu, T. Ying   +10 more
semanticscholar   +1 more source

B cell analyses after SARS-CoV-2 mRNA third vaccination reveals a hybrid immunity like antibody response

Nature Communications, 2023
SARS-CoV-2 vaccines and infection induce antibody responses but the evolution of subsequent variants has resulted in the development of escape mutants.
Emanuele Andreano, Ida Paciello, Giulio Pierleoni, Giulia Piccini, Valentina Abbiento, Giada Antonelli, Piero Pileri, Noemi Manganaro, Elisa Pantano, Giuseppe Maccari, Silvia Marchese, Lorena Donnici, Linda Benincasa, Ginevra Giglioli, Margherita Leonardi, Concetta De Santi, Massimiliano Fabbiani, Ilaria Rancan, Mario Tumbarello, Francesca Montagnani, Claudia Sala, Duccio Medini, Raffaele De Francesco, Emanuele Montomoli, Rino Rappuoli   +24 more
doaj   +1 more source

A human monoclonal antibody blocking SARS-CoV-2 infection

Nature Communications, 2020
The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking.
Chunyan Wang, Wentao Li, D. Drabek, Nisreen M. A. Okba, R. van Haperen, A. Osterhaus, F. V. van Kuppeveld, B. Haagmans, F. Grosveld, B. Bosch   +9 more
semanticscholar   +1 more source

A Case of Light Chain Deposition Disease Leading to Acute Liver Failure and Review of Literature

Diseases, 2023
Light chain deposition disease (LCDD) is a monoclonal immunoglobulin deposition disease characterized by light chain deposition in soft tissues and viscera, causing systemic organ dysfunction with an underlying lymphoproliferative disorder.
Mustafa Gandhi, Syed Bilal Pasha, Emily Reznicek, Syed Raheel Pasha, Hamza Ertugrul, Adel Araslanova, Feng Yin, Veysel Tahan   +7 more
doaj   +1 more source

Production of monoclonal antibodies against recombinant nucleoprotein of avian influenza virus, serotype H9N2 [PDF]

Iranian Journal of Veterinary Medicine, 2018
Background: Avian influenza viruses (AIVs) including the subtype H9N2 cause considerable financial losses to poultry industries. Rapid and accurate diagnosis of avian influenza (AI) infection is important in control and eradication programs.
Masoudreza Seyfiabad Shapouri, Azadeh Yektaseresht, Masoud Ghorbanpoor Najafabadi, Amin Jaydari   +3 more
doaj   +1 more source

Discrimination of human cytotoxic lymphocytes from regulatory and B-lymphocytes by orthogonal light scattering [PDF]

, 1986
Light scattering properties of human lymphocyte subpopulations selected by immunofluorescence were studied with a flow cytometer. Regulatory and B-lymphocytes showed a low orthogonal light scatter signal, whereas cytotoxic lymphocytes identified with leu-
Berkel, W. van, Greve, J., Grooth, B.G. de, Napel, C.H.H. ten, Terstappen, L.W.M.M.   +4 more
core   +9 more sources